<DOC>
	<DOC>NCT01429441</DOC>
	<brief_summary>The purpose of this study is to evaluate the treatment of symptomatic vitreomacular adhesion / (VMT) including macular hole with ocriplasmin.</brief_summary>
	<brief_title>Ocriplasmin for Treatment for Symptomatic Vitreomacular Adhesion Including Macular Hole</brief_title>
	<detailed_description>The present study is designed to assess anatomical and functional outcomes following a single intravitreal injection of ocriplasmin 0.125mg in subjects with symptomatic vitreomacular adhesion (VMA)/ (VMT) including macular hole.</detailed_description>
	<mesh_term>Tissue Adhesions</mesh_term>
	<mesh_term>Retinal Perforations</mesh_term>
	<criteria>Subjects 18 years of age or older and of either gender Presence of vitreomacular adhesion Best corrected visual acuity (BCVA) of 20/32 or worse in study eye BCVA of 20/800 or better in the nonstudy eye History or current evidence of proliferative retinopathy, exudative agerelated macular degeneration (AMD) or retinal vein occlusion in the study eye Any vitreous hemorrhage or any other vitreous opacification which precludes the visualization of the posterior pole by visual inspection OR adequate assessment of the macula by spectraldomain optical coherence tomography (SDOCT) in the study eye Macular hole of &gt; 400 Âµm diameter in the study eye Presence of epiretinal membrane (ERM) Aphakia in the study eye High myopia (more than 8D) in study eye History of rhegmatogenous retinal detachment in either eye History of vitrectomy in the study eye Previous participation in this trial or prior administration of ocriplasmin in the study eye</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
</DOC>